Get the Stockscreener App
1.171
6.13%
-0.0765
Chromocell Therapeutics Corp stock is traded at $1.171, with a volume of 9,048.
It is down -6.13% in the last 24 hours and up +17.10% over the past month.
Chromocell Therapeutics Corp is a clinical-stage biotechnology company focused on developing and commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain and other associated medical conditions. The company's initial clinical focus is to selectively target the sodium ion-channel known as NaV1.7 for the treatment of various types of chronic neuropathic pain and eye pain. The Company's portfolio also includes pre-clinical work on other sodium channel receptor subtypes, and the company intends to explore these and other compounds for the treatment of additional pain indications.
See More
Previous Close:
$1.2475
Open:
$1.2
24h Volume:
9,048
Relative Volume:
0.01
Market Cap:
$8.52M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-13.26%
1M Performance:
+17.10%
6M Performance:
+98.47%
1Y Performance:
+0.00%
1-Day Range:
$1.16
$1.20
1-Week Range:
$1.16
$1.3699
52-Week Range:
$0.45
$3.80
Chromocell Therapeutics Corp Stock (CHRO) Company Profile
Name
Chromocell Therapeutics Corp
Sector
Industry
Phone
(917) 644-6313
Address
685 US HIGHWAY ONE, NORTH BRUNSWICK
Compare CHRO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CHRO
Chromocell Therapeutics Corp
|
1.18 | 8.52M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
447.00 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
513.42 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.29 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
542.34 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
256.81 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Chromocell Therapeutics Corp Stock (CHRO) Latest News
Channel Therapeutics Faces Financial Uncertainty as Auditors Issue Going Concern Warning - Stock Titan
Ligand Pharmaceuticals to Merge Units With Channel Therapeutics to Launch Pelthos Therapeutics - marketscreener.com
Gold Falls Over 1%; D.R. Horton Posts Downbeat Earnings - Benzinga
Ligand subsidiaries, Chromocell Therapeutics to merge - TipRanks
Ligand Subsidiary Pelthos Therapeutics To Combine With Channel Therapeutics - marketscreener.com
Ligand Subsidiary Pelthos Therapeutics to Combine with Channel Therapeutics - GlobeNewswire Inc.
Channel Therapeutics Corporation announced that it has received $0.25 million in funding -February 24, 2025 - Marketscreener.com
Channel Therapeutics secures $325,000 promissory note By Investing.com - Investing.com Australia
Channel Therapeutics secures $325,000 promissory note - Investing.com India
New Biotech Stocks at Investorideas.com - Investorideas.com newswire
Wall Street-Heavily Traded - WDRB
Biopharma IPOs rebound slightly, as class of 2024 lags with a 29% average decline - BioWorld Online
Channel Therapeutics Advances Novel Pain Treatment Strategy with NaV1.7 Inhibitor Pipeline - StockTitan
Channel Therapeutics' Pain Treatment Breakthrough: Novel Nerve Block Outperforms Standard Care in Key Trial - StockTitan
Chromocell changes name to Channel Therapeutics, provides program updates - Nasdaq
Channel Therapeutics finalizes corporate restructuring - Investing.com
Chromocell Announces Unveiling of Injectable Depot Program for the Treatment of Surgical Pain - The Manila Times
Chromocell to Present at Upcoming Fall Investor Conferences - StockTitan
Chromocell Therapeutics amends stock repurchase plan - TradingPedia
Chromocell Announces Amendment to Stock Repurchase Plan | CHRO Stock News - StockTitan
Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing - GlobeNewswire
Another Delaware Publicly Traded Company Proposes A Nevada Move | Allen Matkins - JD Supra
Chromocell to Participate in Life Sciences Investor Forum September 19th - Yahoo Finance
CDMO Benuvia Appoints Terry Novak As New CEO - Pharmaceutical Online
IPO class of 2024 shows value recovery despite mixed stock performance - BioWorld Online
Healthy Returns: Biotech IPOs ramped up to start 2024, but the market hasn't fully recovered just yet - CNBC
Why Super Micro Computer Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Friday's Mid-Day Session - TradingView
Chromocell Issues Letter to Stockholders from Chief Executive Officer - StockTitan
Chutes & Ladders—Bayer undergoes leadership shake-up - Fierce Biotech
Are there bright times for biotech IPOs ahead? - European Biotechnology Magazine
Sidoti Events, LLC's Virtual March Small-Cap Conference - Yahoo Finance
Chromocell Therapeutics Announces Closing of Initial Public Offering for Gross Proceeds of $6.6 Million - Stock Titan
CHRO Stock Price and Chart — AMEX:CHRO - TradingView
CHROChannel Therapeutics Corporation Latest Stock News & Market Updates - StockTitan
CHRO IPO NewsPain relief biotech Chromocell Therapeutics sets terms for $9 million IPO - renaissancecapital.com
Biotech Venture in the UAE Validated by IPO in the U.S. - PR Newswire
Tina Garyantes – Feliciano Center For Entrepreneurship And Innovation - Montclair State University
Stocks Telegraph - Stocks Telegraph
Nestlé and Chromocell Extend Collaboration to Find Alternatives to Salt - Food Manufacturing
Improving the Reliability and Utility of Streptozotocin‐Induced Rat Diabetic Model - Wiley Online Library
Chromocell Announces Initiation of Multiple Ascending Doses Portion of Phase 1 Clinical Trial - PR Newswire
Chromocell and Astellas Announce FDA Fast Track Designation and First Subject Dosing with Lead Candidate CC8464/ASP1807 for the Management of Neuropathic Pain Associated with iSFN - PR Newswire
News from Central Jersey's pharma, biotech industries - Central New Jersey News
Astellas, Chromocell Launch Up-to-$515M+ Pain Drugs Collaboration - Genetic Engineering and Biotechnology News
Chromocell Therapeutics Corp Stock (CHRO) Financials Data
There is no financial data for Chromocell Therapeutics Corp (CHRO). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
1.59%
0.56%
Cap:
|
Volume (24h):